Canonical and non-canonical barriers facing antimiR cancer therapeutics

Current Medicinal Chemistry

Volumn 20, Issue 29, 2013, Pages 3582-3593

  Cheng, Christopher J ^a,b   Saltzman, W Mark ^a   Slack, J Frank ^b  

^a Yale University   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

AntimiR; Antisense therapeutics; Cancer therapy; Chemical modification; Liposome; MicroRNA inhibition; Oligonucleotide; OncomiR; Polymer nanoparticle; Tumor targeting

Indexed keywords

ANTAGOMIR; CAMPTOTHECIN; CISPLATIN; DEOXYRIBONUCLEOTIDE; DOXORUBICIN; LIPOPROTEIN RECEPTOR; LOCKED NUCLEIC ACID; MACROGOL; MESSENGER RNA; METHOTREXATE; MICRORNA; MICRORNA 122; MICRORNA 155; MICRORNA 29; OLIGONUCLEOTIDE; PEPTIDE NUCLEIC ACID; POLYETHYLENEIMINE; RIBONUCLEASE H; SCAVENGER RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CELL FUSION; CELL MEMBRANE; CELL STRAIN K 562; CELL SURFACE; CHEMICAL MODIFICATION; CIRCULATION TIME; CYTOTOXICITY; ENDOSOME; ENDOTHELIUM CELL; ESCAPE BEHAVIOR; EXOSOME; EXPRESSION VECTOR; EXTRACELLULAR MATRIX; FENESTRATION; HALF LIFE TIME; HUMAN; HYDRODYNAMICS; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; KIDNEY CLEARANCE; LEUKEMIA CELL; LIPID BILAYER; LYMPH VESSEL; LYMPHATIC DRAINAGE; MACROMOLECULE; MACROPHAGE; MONONUCLEAR PHAGOCYTE; NEGATIVE FEEDBACK; NONHUMAN; PHAGOCYTOSIS; PINOCYTOSIS; PROTEIN BINDING; RETICULOENDOTHELIAL SYSTEM; STATIC ELECTRICITY; STOMACH CANCER; STROMA CELL; TISSUE PRESSURE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR XENOGRAFT; URINARY EXCRETION; VASCULAR TUMOR; VASCULARIZATION;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); DRUG STABILITY; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84883249501     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320290004     Document Type: Article

References (132)

1. Bartel, D. P. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell, 2004, 116, 281-297.
2. Guo, H.; Ingolia, N. T.; Weissman, J. S.; Bartel, D. P. Mammalian microRNAs Predominantly Act to Decrease Target mRNA Levels. Nature, 2010, 466, 835-840.
3. Calin, G. A.; Dumitru, C. D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; Rassenti, L.; Kipps, T.; Negrini, M.; Bullrich, F.; Croce, C.M. Frequent Deletions and Down-regulation of Micro-RNA Genes miR15 and miR16 at 13q14 in Chronic Lymphocytic Leukemia. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 15524-15529.
4. Johnson, S. M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; Reinert, K. L.; Brown, D.; Slack, F. J. RAS Is Regulated by the Let-7 microRNA Family. Cell, 2005, 120, 635-647.
5. He, L.; Thomson, J. M.; Hemann, M. T.; Hernando-Monge, E.; Mu, D.; Goodson, S.; Powers, S.; Cordon-Cardo, C.; Lowe, S. W.; Hannon, G. J.; Hammond, S.M. A microRNA Polycistron as a Potential Human Oncogene. Nature, 2005, 435, 828-833.
6. Schroeder, A.; Heller, D. A.; Winslow, M. M.; Dahlman, J. E.; Pratt, G. W.; Langer, R.; Jacks, T.; Anderson, D. G. Treating Metastatic Cancer with Nanotechnology. Nat. Rev. Cancer., 2011, 12, 39-50.
7. Vester, B.; Wengel, J. LNA (locked Nucleic Acid): High-affinity Targeting of Complementary RNA and DNA. Biochemistry, 2004, 43, 13233-13241.
8. Lanford, R. E.; Hildebrandt-Eriksen, E. S.; Petri, A.; Persson, R.; Lindow, M.; Munk, M. E.; Kauppinen, S.; Ørum, H. Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection. Science, 2010, 327, 198-201.
9. Esau, C. C. Inhibition of microRNA with Antisense Oligonucleotides. Methods, 2008, 44, 55-60.
10. Seto, A. G. The Road Toward microRNA Therapeutics. Int. J. Biochem. Cell. Biol., 2010, 42, 1298-1305.
11. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in Vivo with 'antagomirs'. Nature, 2005, 438, 685-689.
12. Wolfrum, C.; Shi, S.; Jayaprakash, K. N.; Jayaraman, M.; Wang, G.; Pandey, R. K.; Rajeev, K. G.; Nakayama, T.; Charrise, K.; Ndungo, E. M.; Zimmermann, T.; Koteliansky, V.; Manoharan, M.; Stoffel M. Mechanisms and Optimization of in Vivo Delivery of Lipophilic siRNAs. Nat. Biotech., 2007, 25, 1149-1157.
13. Summerton, J.; Weller, D. Morpholino Antisense Oligomers: Design, Preparation, and Properties. Antisense Nucleic Acid Drug Dev., 1997, 7, 187-195.
14. Nielsen, P. E.; Egholm, M.; Berg, R. H.; Buchardt, O. Sequenceselective Recognition of DNA by Strand Displacement with a Thymine-substituted Polyamide. Science, 1991, 254, 1497-1500.
15. Shiraishi, T.; Nielsen, P. E. Enhanced Delivery of Cell-penetrating Peptide-peptide Nucleic Acid Conjugates by Endosomal Disruption. Nat. Protocols, 2006, 1, 633-636.
16. Moulton, H. M.; Fletcher, S.; Neuman, B. W.; McClorey, G.; Stein, D. A.; Abes, S.; Wilton, S. D.; Buchmeier, M. J.; Lebleu, B.; Iversen, P. L. Cell-penetrating Peptide-morpholino Conjugates Alter pre-mRNA Splicing of DMD (Duchenne Muscular Dystrophy) and Inhibit Murine Coronavirus Replication in Vivo. Biochem. Soc. Trans., 2007, 35, 826-828.
17. Torchilin, V. P. Recent Advances with Liposomes as Pharmaceutical Carriers. Nat. Rev. Drug Discov., 2005, 4, 145-160.
18. Cho, K.; Wang, X.; Nie, S.; Chen, Z. (Georgia); Shin, D. M. Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin. Cancer Res., 2008, 14, 1310-1316.
19. Haussecker, D. The Business of RNAi Therapeutics in 2012. Mol. Ther. Nucleic Acids, 2012, 1, e8.
20. Burnett, J. C.; Rossi, J. J.; Tiemann, K. Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol. J., 2011, 6, 1130-1146.
21. Dias, N.; Stein, C. Potential Roles of Antisense Oligonucleotides in Cancer Therapy. The Example of Bcl-2 Antisense Oligonucleotides. Eur. J. Pharm. Biopharm., 2002, 54, 263-269.
22. Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological Barriers to Therapy with Antisense and siRNA Oligonucleotides. Mol. Pharm., 2009, 6, 686-695.
23. Geary, R. S.; Yu, R. Z.; Levin, A. A. Pharmacokinetics of Phosphorothioate Antisense Oligodeoxynucleotides. Curr. Opin. Investig. Drugs., 2001, 2, 562-573.
24. Yu, R. Z.; Kim, T.-W.; Hong, A.; Watanabe, T. A.; Gaus, H. J.; Geary, R. S. Cross-species Pharmacokinetic Comparison from Mouse to Man of a Second-generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100. Drug Metab. Dispos., 2007, 35, 460-468.
25. McMahon, B. M.; Mays, D.; Lipsky, J.; Stewart, J. A.; Fauq, A.; Richelson, E. Pharmacokinetics and Tissue Distribution of a Peptide Nucleic Acid After Intravenous Administration. Antisense Nucleic Acid Drug Dev., 2002, 12, 65-70.
26. Amantana, A.; Moulton, H. M.; Cate, M. L.; Reddy, M. T.; Whitehead, T.; Hassinger, J. N.; Youngblood, D. S.; Iversen, P. L. Pharmacokinetics, Biodistribution, Stability and Toxicity of a Cellpenetrating Peptide-morpholino Oligomer Conjugate. Bioconjug. Chem., 2007, 18, 1325-1331.
27. Torres, A. G.; Fabani, M. M.; Vigorito, E.; Williams, D.; Al-Obaidi, N.; Wojciechowski, F.; Hudson, R. H. E.; Seitz, O.; Gait, M. J. Chemical Structure Requirements and Cellular Targeting of microRNA-122 by Peptide Nucleic Acids anti-miRs. Nucleic Acids Res., 2012, 40, 2152-2167.
28. Järver, P.; Coursindel, T.; Andaloussi, S. E.; Godfrey, C.; Wood, M. J.; Gait, M. J. Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. Mol. Ther. Nucleic Acids., 2012, 1, e27.
29. Cai, L.; Wang, X.; Wang, W.; Qiu, N.; Wen, J.; Duan, X.; Li, X.; Chen, X.; Yang, L.; Qian, Z.; Wei, Y.; Chen, L. Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo. Int. J. Nanomedicine., 2012, 7, 4499-4510.
30. Hrkach, J.; Hoff, D. Von; Ali, M. M.; Andrianova, E.; Auer, J.; Campbell, T.; Witt, D. De; Figa, M.; Figueiredo, M.; Horhota, A.; Low, S.; McDonnell, K.; Peeke, E.; Retnarajan, B.; Sabnis, A.; Schnipper, E.; Song, J. J.; Song, Y. H., Summa, J.; Tompsett, D.; Troiano, G.; Van Geen Hoven, T.; Wright, J.; LoRusso, P.; Kantoff, P.W.; Bander, N.H.; Sweeney, C.; Farokhzad, O.C.; Langer, R.; Zale, S. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile. Sci. Transl. Med., 2012, 4, 128ra39.
31. Park, J. W. Liposome-based Drug Delivery in Breast Cancer Treatment. Breast Cancer Res., 2002, 4, 95-99.
32. White, P. J.; Anastasopoulos, F.; Pouton, C. W.; Boyd, B. J. Overcoming Biological Barriers to in Vivo Efficacy of Antisense Oligonucleotides. Expert Rev. Mol. Med., 2009, 11, e10.
33. Fattal, E.; Barratt, G. Nanotechnologies and Controlled Release Systems for the Delivery of Antisense Oligonucleotides and Small Interfering RNA. Br. J. Pharmacol., 2009, 157, 179-194.
34. Choi, H. S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J. P.; Ipe, B. I.; Bawendi, M. G.; Frangioni, J. V. Renal Clearance of Nanoparticles. Nat. Biotechnol., 2007, 25, 1165-1170.
35. Krieg, A. M.; Stein, C. A. Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-protein? Antisense Res. Dev., 1995, 5, 241.
36. Bijsterbosch, M. K.; Manoharan, M.; Rump, E. T.; Vrueh, R. L. De; Veghel, R. van; Tivel, K. L.; Biessen, E. A.; Bennett, C. F.; Cook, P. D.; Berkel, T. J. van In Vivo Fate of Phosphorothioate Antisense Oligodeoxynucleotides: Predominant Uptake by Scavenger Receptors on Endothelial Liver Cells. Nucleic Acids Res., 1997, 25, 3290-3296.
37. Butler, M.; Crooke, R. M.; Graham, M. J.; Lemonidis, K. M.; Lougheed, M.; Murray, S. F.; Witchell, D.; Steinbrecher, U.; Bennett, C. F. Phosphorothioate Oligodeoxynucleotides Distribute Similarly in Class A Scavenger Receptor Knockout and Wild-type Mice. J. Pharmacol. Exp. Ther., 2000, 292, 489-496.
38. Bijsterbosch, M. K.; Manoharan, M.; Dorland, R.; Veghel, R. Van; Biessen, E. A. L.; Berkel, T. J. C. Van bis-Cholesteryl-conjugated Phosphorothioate Oligodeoxynucleotides Are Highly Selectively Taken up by the Liver. J. Pharmacol. Exp. Ther., 2002, 302, 619-626.
39. Albanese, A.; Tang, P. S.; Chan, W. C. W. The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems. Annu. Rev. Biomed. Eng., 2012, 14, 1-16.
40. Owens, D. E.; Peppas, N. A. Opsonization, Biodistribution, and Pharmacokinetics of Polymeric Nanoparticles. Int. J. Pharm., 2006, 307, 93-102.
41. Elmen, J.; Lindow, M.; Schutz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjarn, M.; Hansen, H. F.; Berger, U.; Gullans, S.; Kearney, P.; Sarnow, P.; Straarup, E.M.; Kauppinen, S. LNA-mediated microRNA Silencing in Non-human Primates. Nature, 2008, 452, 896-899.
42. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J. W.; Thurston, G.; Roberge, S.; Jain, R. K.; McDonald, D. M. Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness. Am. J. Pathol., 2000, 156, 1363-1380.
43. Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res., 1986, 46, 6387-6392.
44. Fluiter, K.; Asbroek, A. L. M. A. ten; Wissel, M. B. de; Jakobs, M. E.; Wissenbach, M.; Olsson, H.; Olsen, O.; Oerum, H.; Baas, F. In Vivo Tumor Growth Inhibition and Biodistribution Studies of Locked Nucleic Acid (LNA) Antisense Oligonucleotides. Nucleic Acids Res., 2003, 31, 953-962.
45. Zhang, Y.; Roccaro, A. M.; Rombaoa, C.; Flores, L.; Obad, S.; Fernandes, S. M.; Sacco, A.; Liu, Y.; Ngo, H.; Quang, P.; Azab, A.K.; Azab, F.; Maiso, P.; Reagan, M.; Brown, J.R.; Thai, T.H.; Kauppinen, S.; Ghobrial, I.M. LNA-mediated anti-miR-155 Silencing in Low-grade B-cell Lymphomas. Blood, 2012, 120, 1678-1686.
46. Anand, S.; Majeti, B. K.; Acevedo, L. M.; Murphy, E. A.; Mukthavaram, R.; Scheppke, L.; Huang, M.; Shields, D. J.; Lindquist, J. N.; Lapinski, P. E.; King, P.D.; Weis, S.M.; Cheresh, D.A. MicroRNA-132-mediated Loss of p120RasGAP Activates the Endothelium to Facilitate Pathological Angiogenesis. Nat. Med., 2010, 16, 909-914.
47. Plummer, P. N.; Freeman, R.; Taft, R. J.; Vider, J.; Sax, M.; Umer, B. A.; Gao, D.; Johns, C.; Mattick, J. S.; Wilton, S. D.; Ferro, V.; McMillan, N.A.; Swarbrick, A.; Mittal, V.; Mellick, A.S. MicroRNAs Regulate Tumor Angiogenesis Modulated by Endothelial Progenitor Cells. Cancer Res., 2013, 73, 341-352.
48. Babar, I. A.; Cheng, C. J.; Booth, C. J.; Liang, X.; Weidhaas, J. B.; Saltzman, W. M.; Slack, F. J. Nanoparticle-based Therapy in an in Vivo microRNA-155 (miR-155)-dependent Mouse Model of Lymphoma. Proc. Natl. Acad. Sci. U. S. A., 2012, 109, E1695-E1704.
49. Chauhan, V.; Stylianopoulos, T.; Martin, J.; Popovic, Z.; Chen, O.; Bawendi, M.; Fukumura, D.; Jain, R. K. Normalization of tumour blood vessels improves the delivery of nanomedicines in a sizedependent manner. Nat. Nanotechnol., 2012, 7, 383-388.
50. Jain, R. K.; Stylianopoulos, T. Delivering Nanomedicine to Solid Tumors. Nat. Rev. Clin. Oncol., 2010, 7, 653-664.
51. Wong, C.; Stylianopoulos, T.; Cui, J.; Martin, J.; Chauhan, V. P.; Jiang, W.; Popovic, Z.; Jain, R. K.; Bawendi, M. G.; Fukumura, D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 2426-2431.
52. Regev, R.; Eytan, G. D. Flip-flop of Doxorubicin Across Erythrocyte and Lipid Membranes. Biochem. Pharmacol., 1997, 54, 1151-1158.
53. Speelmans, G.; Staffhorst, R. W.; Kruijff, B. de; Wolf, F. A. de Transport Studies of Doxorubicin in Model Membranes Indicate a Difference in Passive Diffusion Across and Binding at the Outer and Inner Leaflets of the Plasma Membrane. Biochemistry, 1994, 33, 13761-13768.
54. Holzer, A. K.; Samimi, G.; Katano, K.; Naerdemann, W.; Lin, X.; Safaei, R.; Howell, S. B. The Copper Influx Transporter Human Copper Transport Protein 1 Regulates the Uptake of Cisplatin in Human Ovarian Carcinoma Cells. Mol. Pharmacol., 2004, 66, 817-823.
55. Goldman, I. D.; Matherly, L. H. The Cellular Pharmacology of Methotrexate. Pharmacol. Ther., 1985, 28, 77-102.
56. Gupta, E.; Luo, F.; Lallo, A.; Ramanathan, S.; Vyas, V.; Rubin, E.; Sinko, P. The Intestinal Absorption of Camptothecin, a Highly Lipophilic Drug, Across Caco-2 Cells Is Mediated by Active Transporter(s). Anticancer Res., 2000, 20, 1013-1016.
57. Akhtar, S.; Basu, S.; Wickstrom, E.; Juliano, R. L. Interactions of Antisense DNA Oligonucleotide Analogs with Phospholipid Membranes (liposomes). Nucleic Acids Res., 1991, 19, 5551-5559.
58. Loke, S. L.; Stein, C. A.; Zhang, X. H.; Mori, K.; Nakanishi, M.; Subasinghe, C.; Cohen, J. S.; Neckers, L. M. Characterization of Oligonucleotide Transport into Living Cells. Proc. Natl. Acad. Sci. U. S. A., 1989, 86, 3474-3478.
59. Vlassov, V. V.; Balakireva, L. A.; Yakubov, L. A. Transport of Oligonucleotides Across Natural and Model Membranes. Biochim. Biophys. Acta, 1994, 1197, 95-108.
60. Yakubov, L. A.; Deeva, E. A.; Zarytova, V. F.; Ivanova, E. M.; Ryte, A. S.; Yurchenko, L. V.; Vlassov, V. V. Mechanism of Oligonucleotide Uptake by Cells: Involvement of Specific Receptors? Proc. Natl. Acad. Sci. U. S. A., 1989, 86, 6454-6458.
61. Diesbach, P. de; Berens, C.; N'Kuli, F.; Monsigny, M.; Sonveaux, E.; Wattiez, R.; Courtoy, P. J. Identification, Purification and Partial Characterisation of an Oligonucleotide Receptor in Membranes of HepG2 Cells. Nucl. Acids Res., 2000, 28, 868-874.
62. Gray, G. D.; Basu, S.; Wickstrom, E. Transformed and Immortalized Cellular Uptake of Oligodeoxynucleoside Phosphorothioates, 3'-alkylamino Oligodeoxynucleotides, 2'-O-methyl Oligoribonucleotides, Oligodeoxynucleoside Methylphosphonates, and Peptide Nucleic Acids. Biochem. Pharmacol., 1997, 53, 1465-1476.
63. Dias, N.; Stein, C. A. Antisense Oligonucleotides: Basic Concepts and Mechanisms. Mol. Cancer Ther., 2002, 1, 347-355.
64. Koller, E.; Vincent, T. M.; Chappell, A.; De, S.; Manoharan, M.; Bennett, C. F. Mechanisms of Single-stranded Phosphorothioate Modified Antisense Oligonucleotide Accumulation in Hepatocytes. Nucleic Acids Res., 2011.
65. Lebedeva, I.; Benimetskaya, L.; Stein, C. A.; Vilenchik, M. Cellular Delivery of Antisense Oligonucleotides. Eur. J. Pharm. Biopharm., 2000, 50, 101-119.
66. Obad, S.; Santos, C. O. dos; Petri, A.; Heidenblad, M.; Broom, O.; Ruse, C.; Fu, C.; Lindow, M.; Stenvang, J.; Straarup, E. M.; Hansen, H.F.; Koch, T.; Pappin, D.; Hannon, G.J.; Kauppinen, S. Silencing of microRNA Families by Seed-targeting Tiny LNAs. Nat. Genet., 2011, 43, 371-378.
67. Fontana, L.; Fiori, M. E.; Albini, S.; Cifaldi, L.; Giovinazzi, S.; Forloni, M.; Boldrini, R.; Donfrancesco, A.; Federici, V.; Giacomini, P.; Peschle, C.; Fruci, D. Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma Through P21 and BIM. PLoS ONE, 2008, 3, e2236.
68. Brock, M.; Samillan, V. J.; Trenkmann, M.; Schwarzwald, C.; Ulrich, S.; Gay, R. E.; Gassmann, M.; Ostergaard, L.; Gay, S.; Speich, R.; Huber, L.C. AntagomiR Directed Against miR-20a Restores Functional BMPR2 Signalling and Prevents Vascular Remodelling in Hypoxia-induced Pulmonary Hypertension. Eur. Heart J., 2012. Available from: http://eurheartj.oxfordjournals.org/ content/early/2012/03/25/eurheartj.ehs060.long
69. Soifer, H. S.; Koch, T.; Lai, J.; Hansen, B.; Hoeg, A.; Oerum, H.; Stein, C. A. Silencing of Gene Expression by Gymnotic Delivery of Antisense Oligonucleotides. Functional Genomics; Kaufmann, M.; Klinger, C., Eds.; Springer New York: New York, NY, 2012; Vol. 815, pp. 333-346.
70. Summerton, J. E. Endo-Porter: a Novel Reagent for Safe, Effective Delivery of Substances into Cells. Ann. N. Y. Acad. Sci., 2005, 1058, 62-75.
71. Schroit, A. J.; Madsen, J.; Nayar, R. Liposome-cell Interactions: In Vitro Discrimination of Uptake Mechanism and in Vivo Targeting Strategies to Mononuclear Phagocytes. Chem. Phys. Lipids, 1986, 40, 373-393.
72. Davda, J.; Labhasetwar, V. Characterization of Nanoparticle Uptake by Endothelial Cells. Int. J. Pharm., 2002, 233, 51-9.
73. Cartiera, M. S.; Johnson, K. M.; Rajendran, V.; Caplan, M. J.; Saltzman, W. M. The Uptake and Intracellular Fate of PLGA Nanoparticles in Epithelial Cells. Biomaterials, 2009, 30, 2790-2798.
74. Pollock, S.; Antrobus, R.; Newton, L.; Kampa, B.; Rossa, J.; Latham, S.; Nichita, N. B.; Dwek, R. A.; Zitzmann, N. Uptake and Trafficking of Liposomes to the Endoplasmic Reticulum. FASEB J., 2010, 24, 1866-1878.
75. Rejman, J.; Oberle, V.; Zuhorn, I. S.; Hoekstra, D. Size-dependent Internalization of Particles via the Pathways of Clathrin-and Caveolae-mediated Endocytosis. Biochem. J., 2004, 377, 159-169.
76. Schroit, A. J.; Madsen, J.; Nayar, R. Liposome-cell Interactions: In Vitro Discrimination of Uptake Mechanism and in Vivo Targeting Strategies to Mononuclear Phagocytes. Chem. Phys. Lipids, 1986, 40, 373-393.
77. Gratton, S. E. A.; Ropp, P. A.; Pohlhaus, P. D.; Luft, J. C.; Madden, V. J.; Napier, M. E.; DeSimone, J. M. The Effect of Particle Design on Cellular Internalization Pathways. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 11613-11618.
78. Hafez, I. M.; Maurer, N.; Cullis, P. R. On the Mechanism Whereby Cationic Lipids Promote Intracellular Delivery of Polynucleic Acids. Gene Ther., 2001, 8, 1188-1196.
79. Borgatti, M.; Breda, L.; Cortesi, R.; Nastruzzi, C.; Romanelli, A.; Saviano, M.; Bianchi, N.; Mischiati, C.; Pedone, C.; Gambari, R. Cationic Liposomes as Delivery Systems for Double-stranded PNA-DNA Chimeras Exhibiting Decoy Activity Against NF-κB Transcription Factors. Biochem. Pharmacol., 2002, 64, 609-616.
80. Su, J.; Baigude, H.; McCarroll, J.; Rana, T. M. Silencing microRNA by Interfering Nanoparticles in Mice. Nucleic Acids Res., 2011, 39, e38.
81. Jin, H.; Yu, Y.; Chrisler, W. B.; Xiong, Y.; Hu, D.; Lei, C. Delivery of MicroRNA-10b with Polylysine Nanoparticles for Inhibition of Breast Cancer Cell Wound Healing. Breast Cancer (Auckl), 2012, 6, 9-19.
82. Leamon, C. P.; Cooper, S. R.; Hardee, G. E. Folate-liposomemediated Antisense Oligodeoxynucleotide Targeting to Cancer Cells: Evaluation in Vitro and in Vivo. Bioconjug. Chem., 2003, 14, 738-747.
83. Lee, R. J.; Low, P. S. Folate-mediated Tumor Cell Targeting of Liposome-entrapped Doxorubicin in Vitro. Biochim. Biophys. Acta, 1995, 1233, 134-144.
84. Monia, B. P.; Johnston, J. F.; Sasmor, H.; Cummins, L. L. Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-ras. J. Biol. Chem., 1996, 271, 14533-14540.
85. Thierry, A. R.; Dritschilo, A. Intracellular Availability of Unmodified, Phosphorothioated and Liposomally Encapsulated Oligodeoxynucleotides for Antisense Activity. Nucleic Acids Res., 1992, 20, 5691-5698.
86. Juliano, R. L.; Ming, X.; Nakagawa, O. Cellular Uptake and Intracellular Trafficking of Antisense and siRNA Oligonucleotides. Bioconjugate Chem., 2012, 23, 147-157.
87. Akinc, A.; Thomas, M.; Klibanov, A. M.; Langer, R. Exploring Polyethylenimine-mediated DNA Transfection and the Proton Sponge Hypothesis. J. Gene Med., 2005, 7, 657-663.
88. Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J. Toxicity of Cationic Lipids and Cationic Polymers in Gene Delivery. J. Control. Release, 2006, 114, 100-109.
89. Wharton, S. A.; Martin, S. R.; Ruigrok, R. W.; Skehel, J. J.; Wiley, D. C. Membrane Fusion by Peptide Analogues of Influenza Virus Haemagglutinin. J. Gen. Virol., 1988, 69 ( Pt 8), 1847-1857.
90. Ye, S.; Tian, M.; Wang, T.; Ren, L.; Wang, D.; Shen, L.; Shang, T. Synergistic Effects of Cell-penetrating Peptide Tat and Fusogenic Peptide HA2-enhanced Cellular Internalization and Gene Transduction of Organosilica Nanoparticles. Nanomedicine, 2012, 8, 833-841.
91. Gottschalk, S.; Sparrow, J. T.; Hauer, J.; Mims, M. P.; Leland, F. E.; Woo, S. L.; Smith, L. C. A Novel DNA-peptide Complex for Efficient Gene Transfer and Expression in Mammalian Cells. Gene Ther., 1996, 3, 448-457.
92. Kyriakides, T. R.; Cheung, C. Y.; Murthy, N.; Bornstein, P.; Stayton, P. S.; Hoffman, A. S. pH-Sensitive Polymers That Enhance Intracellular Drug Delivery in Vivo. J. Control. Release, 2002, 78, 295-303.
93. Kobayashi, T.; Stang, E.; Fang, K. S.; Moerloose, P. de; Parton, R. G.; Gruenberg, J. A Lipid Associated with the Antiphospholipid Syndrome Regulates Endosome Structure and Function. Nature, 1998, 392, 193-197.
94. Lu, J. J.; Langer, R.; Chen, J. A Novel Mechanism Is Involved in Cationic Lipid-mediated Functional siRNA Delivery. Mol. Pharm., 2009, 6, 763-771.
95. Ming, X.; Sato, K.; Juliano, R. L. Unconventional Internalization Mechanisms Underlying Functional Delivery of Antisense Oligonucleotides via Cationic Lipoplexes and Polyplexes. J. Control. Release, 2011, 153, 83-92.
96. Kulkarni, M.; Ozgur, S.; Stoecklin, G. On Track with P-bodies. Biochem. Soc. Trans., 2010, 38, 242-251.
97. Eulalio, A.; Behm-Ansmant, I.; Schweizer, D.; Izaurralde, E. PBody Formation Is a Consequence, Not the Cause, of RNAMediated Gene Silencing. Mol. Cell. Biol., 2007, 27, 3970-3981.
98. Gibbings, D. J.; Ciaudo, C.; Erhardt, M.; Voinnet, O. Multivesicular Bodies Associate with Components of miRNA Effector Complexes and Modulate miRNA Activity. Nat. Cell Biol., 2009, 11, 1143-1149.
99. Gibbings, D.; Voinnet, O. Control of RNA Silencing and Localization by Endolysosomes. Trends Cell Biol., 2010, 20, 491-501.
100. Stein, C. A.; Hansen, J. B.; Lai, J.; Wu, S.; Voskresenskiy, A.; Høg, A.; Worm, J.; Hedtjärn, M.; Souleimanian, N.; Miller, P.; Soifer, H.S.; Castanotto, D.; Benimetskaya, L.; Ørum, H.; Koch, T. Efficient Gene Silencing by Delivery of Locked Nucleic Acid Antisense Oligonucleotides, Unassisted by Transfection Reagents. Nucleic Acids Res., 2010, 38, e3.
101. Stoorvogel, W. Functional Transfer of microRNA by Exosomes. Blood, 2012, 119, 646-648.
102. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J. J.; Lötvall, J. O. Exosome-mediated Transfer of mRNAs and microRNAs Is a Novel Mechanism of Genetic Exchange Between Cells. Nat. Cell Biol., 2007, 9, 654-659.
103. Palma, J.; Yaddanapudi, S. C.; Pigati, L.; Havens, M. A.; Jeong, S.; Weiner, G. A.; Weimer, K. M. E.; Stern, B.; Hastings, M. L.; Duelli, D. M. MicroRNAs Are Exported from Malignant Cells in Customized Particles. Nucleic Acids Res., 2012.
104. Ohshima, K.; Inoue, K.; Fujiwara, A.; Hatakeyama, K.; Kanto, K.; Watanabe, Y.; Muramatsu, K.; Fukuda, Y.; Ogura, S.; Yamaguchi, K.; Mochizuki, T. Let-7 MicroRNA Family Is Selectively Secreted into the Extracellular Environment via Exosomes in a Metastatic Gastric Cancer Cell Line. PLoS ONE, 2010, 5, e13247.
105. Umezu, T.; Ohyashiki, K.; Kuroda, M.; Ohyashiki, J. H. Leukemia Cell to Endothelial Cell Communication via Exosomal miRNAs. Oncogene, 2012. Available from: http://www.nature.com/onc/ journal/vaop/ncurrent/full/onc2012295a.html
106. Mitchell, P. S.; Parkin, R. K.; Kroh, E. M.; Fritz, B. R.; Wyman, S. K.; Pogosova-Agadjanyan, E. L.; Peterson, A.; Noteboom, J.; O'Briant, K. C.; Allen, A.; Lin, D.W.; Urban, N.; Drescher, C.W.; Knudsen, B.S.; Stirewalt, D.L.; Gentleman, R.; Vessella, R.L.; Nelson, P.S.; Martin, D.B.; Tewari, M. Circulating microRNAs as Stable Blood-based Markers for Cancer Detection. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 10513-10518.
107. Lee, Y.; Andaloussi, S. E.; Wood, M. J. A. Exosomes and Microvesicles: Extracellular Vesicles for Genetic Information Transfer and Gene Therapy. Hum. Mol. Genet., 2012.
108. Hwang, H.-W.; Wentzel, E. A.; Mendell, J. T. A Hexanucleotide Element Directs microRNA Nuclear Import. Science, 2007, 315, 97-100.
109. Kren, B. T.; Wong, P. Y.-P.; Sarver, A.; Zhang, X.; Zeng, Y.; Steer, C. J. MicroRNAs Identified in Highly Purified Liver-derived Mitochondria May Play a Role in Apoptosis. RNA Biol., 2009, 6, 65-72.
110. Krützfeldt, J.; Kuwajima, S.; Braich, R.; Rajeev, K. G.; Pena, J.; Tuschl, T.; Manoharan, M.; Stoffel, M. Specificity, Duplex Degradation and Subcellular Localization of Antagomirs. Nucleic Acids Res., 2007, 35, 2885-2892.
111. Davis, S.; Propp, S.; Freier, S. M.; Jones, L. E.; Serra, M. J.; Kinberger, G.; Bhat, B.; Swayze, E. E.; Bennett, C. F.; Esau, C. Potent Inhibition of microRNA in Vivo Without Degradation. Nucleic Acids Res., 2009, 37, 70-77.
112. Wahlestedt, C.; Salmi, P.; Good, L.; Kela, J.; Johnsson, T.; Hökfelt, T.; Broberger, C.; Porreca, F.; Lai, J.; Ren, K.; Ossipov, M.; Koshkin, A.; Jakobsen, N.; Skouv, J.; Oerum, H.; Jacobsen, M.H.; Wengel, J. Potent and Nontoxic Antisense Oligonucleotides Containing Locked Nucleic Acids. Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 5633-5638.
113. Lee, J. E.; Bennett, C. F.; Cooper, T. A. RNase H-mediated Degradation of Toxic RNA in Myotonic Dystrophy Type 1. Proc. Natl. Acad. Sci. U. S. A., 2012, 109, 4221-4226.
114. Cheng, C. J.; Slack, F. J. The Duality of oncomiR Addiction in the Maintenance and Treatment of Cancer. Cancer J., 2012, 18, 232-237.
115. Medina, P. P.; Nolde, M.; Slack, F. J. OncomiR Addiction in an in Vivo Model of microRNA-21-induced pre-B-cell Lymphoma. Nature, 2010, 467, 86-90.
116. Corsten, M. F.; Miranda, R.; Kasmieh, R.; Krichevsky, A. M.; Weissleder, R.; Shah, K. MicroRNA-21 Knockdown Disrupts Glioma Growth In Vivo and Displays Synergistic Cytotoxicity with Neural Precursor Cell-Delivered S-TRAIL in Human Gliomas. Cancer Res., 2007, 67, 8994-9000.
117. Kong, W.; He, L.; Coppola, M.; Guo, J.; Esposito, N. N.; Coppola, D.; Cheng, J. Q. MicroRNA-155 Regulates Cell Survival, Growth, and Chemosensitivity by Targeting FOXO3a in Breast Cancer. J. Biol. Chem., 2010, 285, 17869-17879.
118. Woodrow, K. A.; Cu, Y.; Booth, C. J.; Saucier-Sawyer, J. K.; Wood, M. J.; Saltzman, W. M. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with smallinterfering RNA. Nat. Mater., 2009, 8, 526-533.
119. Cheng, C. J.; Saltzman, W. M. Polymer Nanoparticle-mediated Delivery of microRNA Inhibition and Alternative Splicing. Mol. Pharm., 2012, 9, 1481-1488.
120. Ebert, M. S.; Sharp, P. A. MicroRNA Sponges: Progress and Possibilities. RNA, 2010, 16, 2043-2050.
121. Darido, C.; Georgy, S. R.; Wilanowski, T.; Dworkin, S.; Auden, A.; Zhao, Q.; Rank, G.; Srivastava, S.; Finlay, M. J.; Papenfuss, A. T.; Pandolfi, P. P.; Pearson, R. B.; Jane, S. M. Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis. Cancer Cell, 2011, 20, 635-648.
122. Haraguchi, T.; Ozaki, Y.; Iba, H. Vectors Expressing Efficient RNA Decoys Achieve the Long-term Suppression of Specific microRNA Activity in Mammalian Cells. Nucleic Acids Res., 2009, 37, e43.
123. Thomas, C. E.; Ehrhardt, A.; Kay, M. A. Progress and Problems with the Use of Viral Vectors for Gene Therapy. Nat. Rev. Genet., 2003, 4, 346-358.
124. Pekarsky, Y.; Croce, C. M. Is miR-29 an Oncogene or Tumor Suppressor in CLL? Oncotarget, 2010, 1, 224-227.
125. Aguda, B. D.; Kim, Y.; Piper-Hunter, M. G.; Friedman, A.; Marsh, C. B. MicroRNA Regulation of a Cancer Network: Consequences of the Feedback Loops Involving miR-17-92, E2F, and Myc. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 19678-19683.
126. Stenvang, J.; Petri, A.; Lindow, M.; Obad, S.; Kauppinen, S. Inhibition of microRNA Function by antimiR Oligonucleotides. Silence, 2012, 3, 1.
127. Hollins, A. J.; Omidi, Y.; Benter, I. F.; Akhtar, S. Toxicogenomics of Drug Delivery Systems: Exploiting Delivery System-induced Changes in Target Gene Expression to Enhance siRNA Activity. J. Drug Target., 2007, 15, 83-88.
128. Omidi, Y.; Barar, J.; Akhtar, S. Toxicogenomics of Cationic Lipidbased Vectors for Gene Therapy: Impact of Microarray Technology. Curr. Drug Deliv., 2005, 2, 429-441.
129. Chirila, T. V.; Rakoczy, P. E.; Garrett, K. L.; Lou, X.; Constable, I. J. The Use of Synthetic Polymers for Delivery of Therapeutic Antisense Oligodeoxynucleotides. Biomaterials, 2002, 23, 321-342.
130. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles. Mol. Pharm., 2008, 5, 505-515.
131. Moulton, H. M.; Moulton, J. D. Arginine-rich Cell-penetrating Peptides with Uncharged Antisense Oligomers. Drug Discov. Today, 2004, 9, 870.
132. Rozners, E. Recent Advances in Chemical Modification of Peptide Nucleic Acids. J. Nucleic Acids, 2012, 2012.